France's CBD Import Gap Starts at the Seed Catalog

Photo by sweetlouise via Pixabay.

Futura 75. Fedora 17. Santhica 27. Santhica 70. Felina 32. Those five names are the spine of what a French farmer may legally plant as hemp, and every one was bred for fiber, grain or both.

Set that list beside a statement from the Confédération paysanne: 80 to 85 percent of the CBD sold in France is imported. A country that grows more hemp than any other in Europe is buying most of its CBD abroad.

The usual explanation is regulation: flower bans, enforcement, shifting rules. My argument is that the seed list is the nearer cause. It decides what a farmer can put in the ground before any retail rule applies, and it does not cover the genetics a CBD flower industry would need.

Most coverage of this paradox stays at the shop counter or in the courtroom. This piece follows the supply chain back to the seed packet. Two caveats up front: I have not verified the cannabinoid profile of individual varieties, and I have not read the union's exact wording in its own primary statement. Both need checking, and I say where they matter.

Two Numbers That Should Not Coexist

Start with the two claims. France is widely described as Europe's largest hemp grower, which our earlier piece, Inside France's Industrial Hemp Boom, Europe's Biggest Grower, covered at length. Then there is the farmers' union saying that 80 to 85 percent of CBD sold in France comes from abroad.

A note on sourcing, because it matters here. The 80 to 85 percent figure reached me through our own earlier coverage, which attributed it to the Confédération paysanne. I could not retrieve the union's primary statement while preparing this piece, so read it as the union's estimate, not a measured market audit. Anyone building on it should go to the union's own publication first.

Now the hectare statistic. Area figures count hemp grown for stalk and seed: insulation, paper, animal bedding, oil, food. They tell you how much land carries Cannabis sativa. They say nothing about whether the plant on that land can supply a flower or extract market.

That is the gap in the paradox. A thousand hectares of tall, uniform fiber hemp and a thousand hectares of resinous flower cultivars are both hemp in the national tally. Only one of them feeds a CBD shelf.

The usual explanations for the import share are:

• The flower ban and the legal back-and-forth around it.
• Uneven enforcement and uncertainty for producers.
• Price competition from cheaper foreign supply.

Each has some force. I want to test them against something that sits earlier in the chain and that most commentary skips: the list of seed a farmer is allowed to sow.

What the Common Catalogue Actually Lets a Farmer Plant

French hemp production runs on certified seed of varieties registered in the EU Common Catalogue. In practice the catalogue is a genetics whitelist. If a variety is not on it, a farmer cannot plant it for a legal commercial crop. I am stating the certification mechanics in general terms; the exact rules should be confirmed with GNIS and the current French texts.

The varieties named in the material behind this piece are Futura 75, Fedora 17, Santhica 27, Santhica 70 and Felina 32. They are described as bred for fiber, grain or dual use. I have not confirmed the total number of hemp entries in the Commission's plant variety database, so I will not give one. Check the database directly before quoting a count.

The breeding targets explain why this matters. Fiber and grain breeders select for:

• Stalk height and fiber quality.
• Field uniformity.
• Seed yield.
• Reliably low THC.

Flower breeders select for something else:

• Resin density and trichome coverage.
• Terpene profile.
• Branching and flower structure.
• Flowering time.
• The cannabinoid ratio.

Those are different plants, shaped by different pressures over many generations.

Registration adds a further filter. A variety needs stable, low-THC expression to qualify at all, which favors lines bred conservatively for compliance. Whether any listed variety was bred specifically for cannabinoid content is something I could not verify. If none was, then the list holds no genetics designed for a flower market, and that would be the central fact of this piece. Check each variety's breeder documentation before relying on either reading.

Here is my inference, and it is only that. A farmer working from this list can grow hemp that contains CBD. What that farmer will struggle to produce, at the consistency and quality a flower buyer expects, is a crop selected for flower in the first place.

Why Regulation Is the Wrong First Suspect

The regulatory record is real, and I am not dismissing it. The French arrêté of 30 December 2021 limited hemp use to fiber and seed. The Court of Justice of the EU ruled in the Kanavape case in November 2020 that France could not simply ban CBD lawfully produced in another member state. The Conseil d'État then moved against the flower and leaf ban. Verify each date and outcome on Légifrance and the court sites before citing them, because the details matter and I have not re-read the texts.

The distinction I want to draw is this. Those rules govern what may be sold or used. The catalogue governs what may be planted. A court can reopen a shelf in a week. It cannot create a domestic supply of flower-grade genetics.

Our earlier piece on the reversal of France's CBD flower ban traced what happened when products came back into shops. Read it with this in mind. A reversal lifts a barrier at the retail end. The seed constraint sits upstream, and it stays exactly where it was.

Here is the mechanism in one line, and it is my reading, not a documented finding. When demand is legal but the domestic genetic pool is constrained, buyers fill the gap from countries whose growers use flower-oriented cultivars. The imports follow the genetics.

I do not claim the catalogue is the only barrier. Cost, processing capacity, regulatory uncertainty and market habit all play a part. My claim is narrower: it is the earliest barrier in the chain, and an earlier barrier shapes everything built after it. Fix every retail rule and the seed problem remains.

The Strongest Objection: Price, Scale and the THC Cap

The strongest objection is that none of this is about genetics. Imports may reflect cheaper labor, larger indoor production and extract supply chains that already exist in other countries. If a foreign producer can sell flower or extract for less, French farmers would lose on price even with perfect seed.

There is also the THC cap. France has worked with 0.3 percent THC in the plant, but EU agricultural rules have changed the threshold in recent years, so verify the current figure before relying on it. What matters for breeding is that CBD and THC are linked in many lines. A tight cap limits how far a breeder can push CBD, because pushing one often lifts the other.

I also have to concede that some French farmers do grow catalogue varieties for CBD. That weakens any claim that the list makes domestic CBD impossible, and I am not making it. Possible is not the same as competitive.

Here is where I think the thesis survives. Even if cost is a big part of the story, a flower buyer cannot be satisfied by genetics bred for fiber. A French grower with the cheapest labor in Europe would still be offering a plant selected for stalk. Price competition is partly downstream of the seed problem, because a grower with better-suited genetics could compete on a more even footing.

Three pieces of evidence would settle it, and I do not have them:

1. The share of French CBD output that comes from catalogue varieties.
2. CBD yield per hectare for those varieties against imported flower cultivars.
3. The origin split of imports: which countries, and in what form, flower or extract.

If catalogue varieties turn out to match imported cultivars on yield and quality, my argument is wrong. I would bet they do not, but that is a bet and not a finding.

The Slot a Breeder or Seed Company Could Actually Fill

Here is the chain, in order:

1. Seed.
2. Farm.
3. Drying and processing.
4. Extraction or flower sales.
5. Retail.

The bottleneck I am describing sits at step one. Everything after it inherits whatever the seed allows. That is also why it is the part a breeder or seed company could actually address, unlike retail rules, which a company cannot change.

A variety that could fill the gap would need to meet several conditions:

• Stable low-THC expression within the legal cap.
• A cannabinoid profile suited to flower or extract.
• Registration in the EU Common Catalogue.
• Certified seed production at a scale farmers can buy.

I have not checked the registration requirements or timeline with the catalogue authorities, so I will not give figures. My inference is that the process is slow and demanding, which would explain why few companies attempt it. Slow gates also protect whoever gets through them.

I also looked for a derogation or pilot route for cannabinoid-rich genetics and could not confirm one. If none exists, the Common Catalogue registration route is the one that matters. A reader who knows of a pilot programme should say so, because it would change the practical advice.

One caution. Rules differ by country and change over time. Treat this as analysis, not legal advice, and check current French and EU law, along with your own national rules, before breeding, selling or planting anything.

The next time a national hemp boom is quoted, ask what the planted genetics are bred to produce. Hectares can hide a bottleneck. A big number for hemp area can sit beside a small domestic supply of flower or extract, and the seed list explains how.

If you want an early signal that France is closing its import gap, do not watch the shop windows. Watch the Common Catalogue for new hemp entries, and watch for any change in French rules on cannabinoid-oriented varieties. Genetics move first, and the farms and the statistics follow.

Browse our seed collection.